Qiagen (NYSE:QGEN) Updates Q1 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its first quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.540- for the period, compared to the consensus EPS estimate of 0.600. The company issued revenue guidance of $487.8 million-, compared to the consensus revenue estimate of $511.8 million. Qiagen also updated its FY 2026 guidance to 2.500- EPS.

Analysts Set New Price Targets

Several brokerages recently issued reports on QGEN. Barclays reissued an “overweight” rating and set a $57.89 price objective (up from $55.79) on shares of Qiagen in a report on Monday, December 15th. Citigroup lowered Qiagen from a “buy” rating to a “neutral” rating and decreased their target price for the company from $57.89 to $52.63 in a research report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. UBS Group reaffirmed a “neutral” rating on shares of Qiagen in a research report on Wednesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft downgraded Qiagen from a “buy” rating to a “hold” rating and lifted their target price for the company from $52.00 to $54.00 in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Qiagen has an average rating of “Hold” and an average target price of $53.04.

Qiagen Price Performance

NYSE:QGEN traded down $0.10 during mid-day trading on Wednesday, hitting $51.79. 2,381,654 shares of the company’s stock traded hands, compared to its average volume of 3,079,245. The company has a market cap of $10.94 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 2.49 and a beta of 0.67. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. The firm’s 50 day simple moving average is $49.60 and its 200 day simple moving average is $49.64. Qiagen has a 1 year low of $39.61 and a 1 year high of $57.81.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. Sell-side analysts expect that Qiagen will post 2.26 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Danske Bank A S bought a new position in shares of Qiagen in the third quarter valued at $36,000. Advisory Services Network LLC acquired a new stake in shares of Qiagen in the 3rd quarter valued at $64,000. EverSource Wealth Advisors LLC grew its holdings in Qiagen by 226.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after purchasing an additional 1,802 shares during the last quarter. Osaic Holdings Inc. grew its holdings in Qiagen by 101.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock valued at $185,000 after buying an additional 1,951 shares during the last quarter. Finally, Pitcairn Co. acquired a new position in shares of Qiagen during the second quarter valued at about $208,000. Institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.